EN
ENGN.US enGene Therapeutics Inc.
- Market cap
- USD 162M
- P/E
- -
- P/B
- 0.67x
- ROE
- 19.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2026.
Is ENGN.US undervalued?
Graham numberThe Graham number of enGene Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
enGene Therapeutics Inc. fundamental analysis
No fundamental analysis for enGene Therapeutics Inc. yet.
enGene Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About enGene Therapeutics Inc.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to en…
Full company profileenGene Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
enGene Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | -175K | -323K | -509K | -729K |
| Operating Income | -13.9M | -15.9M | -19.4M | -26.1M | -62.3M | -123M | 46.4M |
| EBITDA | -12.9M | -18.1M | -22.8M | -94.8M | -52.0M | -114M | -126M |
| Net Income | -15.1M | -23.4M | -24.5M | -99.9M | -55.1M | -117M | 44.0M |
| EPS | -0.95 | -1.48 | -1.55 | -4.24 | -1.24 | -2.29 | 0.63 |
| Balance Sheet | |||||||
| Total Assets | - | 131M | 132M | 87.0M | 311M | 221M | 288M |
| Total Liabilities | - | 4.05M | 4.62M | 14.5M | 38.6M | 53.8M | 58.0M |
| Shareholders' Equity | - | 127M | 127M | 72.5M | 273M | 168M | 230M |
| Cash & Short-term Investments | - | 1.07M | 314K | 81.6M | 238M | 194M | 266M |
| Total Debt | - | 4.16M | 32.1M | 9.78M | 25.0M | 31.8M | 33.3M |
| Cash Flow | |||||||
| Operating Cash Flow | -13.1M | -16.0M | -17.6M | -24.7M | -48.3M | -99.2M | -104M |
| Capital Expenditure | 192K | 248K | 153K | 318K | 925K | 1.49M | 335K |
| Free Cash Flow | -13.3M | -16.2M | -17.7M | -25.1M | -49.2M | -101M | -105M |
| Ratios | |||||||
| ROE | - | -18.4% | -19.2% | -137.8% | -20.2% | -69.9% | 19.1% |
| ROA | - | -17.8% | -18.5% | -114.9% | -17.7% | -53.0% | 15.2% |
| Debt to Equity | - | 0.03x | 0.25x | 0.13x | 0.09x | 0.19x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
enGene Therapeutics Inc. dividends
enGene Therapeutics Inc. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:1 on Nov 1, 2023.
Who owns enGene Therapeutics Inc.
- Insiders 0.11%
- Institutions 88.20%
- Public & others 11.69%
- Shares outstanding 67.0M
- Free float 32.3M
Top funds holding ENGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Protea Sectoral Biotech Opps IF USD Acc | 21.7K | 0.03% | 0.00% | Jul 2026 |
| JNL/DFA US Small Cap A | 9.97K | 0.01% | 0.00% | Sep 2026 |
| North Square Kennedy MicroCap I | 7.65K | 0.01% | -35.84% | Jun 2026 |
| Dimensional US Sm Company EUR Acc | 3.79K | 0.01% | -0.29% | Sep 2026 |
| AST Small-Cap Equity Portfolio | 1.38K | 0.00% | 0.00% | Sep 2026 |
| LO Selection The Global Balanced EUR MA | 8.00 | 0.00% | -11.11% | Mar 2026 |
| Dimensional US Core Eq Mkt ETF USD Acc | 6.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding ENGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BML Capital Management LLC | 6.67M | 9.95% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 6.26M | 9.34% | +19.10% | Jun 2026 |
| Perceptive Advisors LLC | 4.82M | 7.20% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 2.68M | 3.99% | 0.00% | Jun 2026 |
| Nextech Invest, Ltd. | 2.32M | 3.47% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 2.10M | 3.14% | +1,474.57% | Jun 2026 |
| Vestal Point Capital LP | 1.67M | 2.49% | 0.00% | Jun 2026 |
| Peapod Lane Capital LLC | 1.10M | 1.64% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 1.01M | 1.50% | -12.33% | Jun 2026 |
| Millennium Management LLC | 967K | 1.44% | +0.72% | Jun 2026 |
| Omega Fund Management LLC | 876K | 1.31% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 830K | 1.24% | +431.52% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 748K | 1.12% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 718K | 1.07% | +366.21% | Jun 2026 |
| Affinity Asset Advisors, LLC | 600K | 0.90% | -1.70% | Jun 2026 |
| UBS Group AG | 509K | 0.76% | 0.00% | Jun 2026 |
| Quadrature Capital Limited | 478K | 0.71% | +1,314.53% | Jun 2026 |
| Eversept Partners, LP | 470K | 0.70% | 0.00% | Jun 2026 |
| Kynam Capital Management, LP | 458K | 0.68% | -66.26% | Jun 2026 |
| Seven Fleet Capital Management LP | 411K | 0.61% | 0.00% | Jun 2026 |
enGene Therapeutics Inc. company profile
- Company name
- enGene Therapeutics Inc.
- Ticker
- ENGN.US
- ISIN
- CA29286X1015
- Exchange
- USA Stocks
- Listed since
- Nov 1, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 81
- Fiscal year end
- October
- Address
- 4868 Rue Levy, Montreal, QC, Canada, H4R 2P1
- Phone
- 514 332 4888
- Website
- engene.com
About enGene Therapeutics Inc.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
enGene Therapeutics Inc. management
4- Mr. Ronald H. W. CooperPresident, CEO & Director · born 1963
- Dr. William J. Grossman M.D., Ph.D.Interim Chief Medical Officer & Director · born 1970
- Ms. Kathleen RichtonSenior VP of Finance, Principal Accounting & Financial Officer and Controller · born 1978
- Ms. Joan ConnollyChief Technology Officer · born 1970